|
1
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osborne CK: Tamoxifen in the treatment of
breast cancer. N Engl J Med. 339:1609–1618. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fredriksson L, Li H and Eriksson U: The
PDGF family: Four gene products form five dimeric isoforms.
Cytokine Growth Factor Rev. 15:197–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ostman A: PDGF receptors-mediators of
autocrine tumor growth and regulators of tumor vasculature and
stroma. Cytokine Growth Factor Rev. 15:275–286. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bergsten E, Uutela M, Li X, Pietras K,
Ostman A, Heldin CH, Alitalo K and Eriksson U: PDGF-D is a
specific, protease-activated ligand for the PDGF beta-receptor. Nat
Cell Biol. 3:512–516. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kazlauskas A: PDGFs and their receptors.
Gene. 614:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heldin CH, Ostman A and Rönnstrand L:
Signal transduction via platelet-derived growth factor receptors.
Biochim Biophys Acta. 1378:F79–F113. 1998.PubMed/NCBI
|
|
9
|
Carvalho I, Milanezi F, Martins A, Reis RM
and Schmitt F: Overexpression of platelet-derived growth factor
receptor alpha in breast cancer is associated with tumour
progression. Breast Cancer Res. 7:R788–R795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim S, You D, Jeong Y, Yu J, Kim SW, Nam
SJ and Lee JE: Berberine down-regulates IL-8 expression through
inhibition of the EGFR/MEK/ERK pathway in triple-negative breast
cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jeon M, Han J, Nam SJ, Lee JE and Kim S:
Elevated IL-1β expression induces invasiveness of triple negative
breast cancer cells and is suppressed by zerumbone. Chem Biol
Interact. 258:126–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hosaka K, Yang Y, Seki T, Fischer C, Dubey
O, Fredlund E, Hartman J, Religa P, Morikawa H, Ishii Y, et al:
Pericyte-fibroblast transition promotes tumor growth and
metastasis. Proc Natl Acad Sci USA. 113:E5618–E5627. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim S, Lee J, Oh SJ, Nam SJ and Lee JE:
Differential effect of EGFR inhibitors on tamoxifen-resistant
breast cancer cells. Oncol Rep. 34:1613–1619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim S, Lee J, Jeon M, Nam SJ and Lee JE:
Elevated TGF-β1 and -β2 expression accelerates the epithelial to
mesenchymal transition in triple-negative breast cancer cells.
Cytokine. 75:151–158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paulsson J, Sjöblom T, Micke P, Pontén F,
Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirström K and Ostman
A: Prognostic significance of stromal platelet-derived growth
factor beta-receptor expression in human breast cancer. Am J
Pathol. 175:334–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai X, Cheng H, Bai Z and Li J: Breast
Cancer Cell Line Classification and Its Relevance with Breast Tumor
Subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCarty MF, Somcio RJ, Stoeltzing O, Wey
J, Fan F, Liu W, Bucana C and Ellis LM: Overexpression of PDGF-BB
decreases colorectal and pancreatic cancer growth by increasing
tumor pericyte content. J Clin Invest. 117:2114–2122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakamura Y, Tanaka F, Yoshikawa Y, Mimori
K, Inoue H, Yanaga K and Mori M: PDGF-BB is a novel prognostic
factor in colorectal cancer. Ann Surg Oncol. 15:2129–2136. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Er P, Qian D, Zhang W, Zhang B, Wei H,
Zhang T, Chen X, Wang Y, Zhao J, Wang Q, et al: The expression of
PDGF-BB predicts curative effect in locally advanced esophageal
squamous cell carcinoma treated by radiotherapy. Aging (Albany NY).
12:6586–6599. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fingas CD, Bronk SF, Werneburg NW, Mott
JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE and Gores GJ:
Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling
in cholangiocarcinoma cells. Hepatology. 54:2076–2088. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JC, Li GY, Wang B, Han SX, Sun X,
Jiang YN, Shen YW, Zhou C, Feng J, Lu SY, et al: Metformin inhibits
metastatic breast cancer progression and improves chemosensitivity
by inducing vessel normalization via PDGF-B downregulation. J Exp
Clin Cancer Res. 38:2352019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang KJ, Wang C, Dai LH, Yang J, Huang H,
Ma XJ, Zhou Z, Yang ZY, Xu WD, Hua MM, et al: Targeting an
Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the
Progression and Chemotherapy Resistance of Bladder Cancer. Clin
Cancer Res. 25:1070–1086. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jechlinger M, Sommer A, Moriggl R, Seither
P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and
Grünert S: Autocrine PDGFR signaling promotes mammary cancer
metastasis. J Clin Invest. 116:1561–1570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Greco C, D'Agnano I, Vitelli G, Vona R,
Marino M, Mottolese M, Zuppi C, Capoluongo E and Ameglio F: c-MYC
deregulation is involved in melphalan resistance of multiple
myeloma: Role of PDGF-BB. Int J Immunopathol Pharmacol. 19:67–79.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cumpănas AA, Cimpean AM, Ferician O,
Ceausu RA, Sarb S, Barbos V, Dema A and Raica M: The Involvement of
PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and
Antivascular Therapy in Renal Cancer. Anticancer Res. 36:2291–2295.
2016.PubMed/NCBI
|
